Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

Teva Pharma Industries Ltd ADR (TEVA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Teva ADR's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
16.26 +0.26    +1.62%
10/05 - Closed. Currency in USD ( Disclaimer )
After Hours
16.20
-0.06
-0.37%
19:33:25 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 13,264,392
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.07 - 16.57
Teva ADR 16.26 +0.26 +1.62%

NYSE:TEVA Financials

 
A brief overview of the NYSE:TEVA financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Teva over time.

Teva Pharmaceutical Industries Limited reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 3,819 million compared to USD 3,661 million a year ago. Net loss was USD 139 million compared to USD 220 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to USD 0.2 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

TEVA Income Statement

Gross margin TTM 48.96%
Operating margin TTM 20.88%
Net Profit margin TTM -2.99%
Return on Investment TTM 9.83%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 3819 4457 3850 3878
Gross Profit 1771 2416 1851 1796
Operating Income 660 1250 761 670
Net Income -139 429 80 -863

TEVA Balance Sheet

Quick Ratio MRQ 0.47
Current Ratio MRQ 0.89
LT Debt to Equity MRQ 227.86%
Total Debt to Equity MRQ 273.95%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 42773 43479 42088 43095
Total Liabilities 35230 35353 34577 35387
Total Equity 7543 8126 7511 7708

TEVA Cash Flow Statement

Cash Flow/Share TTM 1.24
Revenue/Share TTM 14.28
Operating Cash Flow  -0.90%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -124 1184 5 324
Cash From Investing Activities 144 301 184 302
Cash From Financing Activities -151 -576 -576 -55
Net Change in Cash -236 977 -420 494
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd ADR
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni May 09, 2024 8:17AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
One day to ER of Q1
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New price target of 17$ by Barclays analyst
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Mar 23, 2024 9:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1% on a Friday with 9.13M volume someone is buying.
Reply
0 0
Report
TSahi Livnoni
TSahi Livnoni Mar 13, 2024 10:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
Reply
0 0
Report
ritchie lee
ritchie lee Jan 22, 2024 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
long trend starting
Reply
5 0
Report
Ramba Łej
Kubizm Jan 22, 2024 1:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hopefully ! Ive been w8ing for it for 3 y xD
Reply
2 0
Report
Ramba Łej
Kubizm Sep 14, 2023 10:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
11,40 will hold as celling or convert to floor :)?
Reply
0 0
Report
Ramba Łej
Kubizm Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
Reply
2 0
Report
BumHunters Archer
JohnJenga Aug 02, 2023 8:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
25 next year seems quite doable
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email